Portal de Periódicos da CAPES

Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy

1986; Elsevier BV; Volume: 108; Issue: 3 Linguagem: Inglês

10.1016/s0022-3476(86)80907-6

1097-6833

Frederick E. Leickly, Rebecca H. Buckley,

Pharmaceutical studies and practices

Selective IgA deficiency has been associated with the use of various therapeutic agents such as phenytoin, D-penicillamine, and gold. ~'2 In some cases, immunoglobulin A concentrations returned B normal after the drug was discontinued. Recently, sulfasalazine therapy has been associated with selective IgA deficiency in adults given treatment for rheumatoid arthritis 3 and in children given treatment for inflammatory bowel diseases?,5 Some, but not all, patients demonstrated increased IgA levels after discontinuation of sulfasalazine. We report a case in which the use of sulfasalazin e for the therapy of ulcerative colitis was followed by the development not only of persistent IgA deficiency, but of IgG2 subclass deficiency as well.